WebPHESGO should be used as part of a complete treatment regimen for early breast cancer. use after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer that has a high likelihood of coming back. What are the most serious side effects of PHESGO? WebPhesgo® contains pertuzumab, trastuzumab, and hyaluronidase-zzxf. It is best to read this information with our general information about breast cancer. These treatments belong to a group of targeted therapy drugs known as monoclonal antibodies. They both work by targeting specific proteins (receptors).
Phesgo European Medicines Agency
WebJan 1, 2024 · Phesgo 600 mg/600 mg/20,000 units (providing 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units hyaluronidase per 10 mL) single-dose vials: 50242-0260-xx VII. References 1. Phesgo [package insert]. South San Francisco, CA; Genentech, Inc; June 2024. Accessed August 2024. 2. WebPHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). goats of nfl
Genentech: Phesgo® (pertuzumab, trastuzumab, and …
WebMar 2, 2024 · Phesgo contains two active substances, pertuzumab and trastuzumab, which are already authorised for treating early and metastatic HER2-positive breast cancer and … WebNov 1, 2024 · When administered with Phesgo, the recommended initial dose of docetaxel is 75 mg/m 2 administered as an intravenous infusion. The dose may be escalated to 100 mg/m 2 administered every 3 weeks if the initial dose is well tolerated. Administer Phesgo until disease progression or unmanageable toxicity, whichever occurs first. Dose … WebPhesgo PERTUZUMAB (per TOOZ ue mab); TRASTUZUMAB (tras TOO zoo mab); HYALURONIDASE is used to treat breast cancer. Pertuzumab and trastuzumab are a … bone lining cells maintain matrix